Evommune (EVMN) vs Sionna Therapeutics (SION)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Evommune is the larger company by market cap ($230.1 million vs $223.0 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | EVMN | SION |
|---|---|---|
| Share price | $6.34 | $4.94 |
| Market cap | $230.09M | $223.04M |
| 1-day change | +1.93% | +2.49% |
| YTD return | -63.67% | -88.28% |
| 1-year return | — | -83.15% |
| EPS (TTM) | $-3.75 | $-2.16 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $33.20 | $54.97 |
| 52-week low | $6.02 | $4.01 |
| Distance from 52-week high | -80.90% | -91.01% |
| Analyst consensus | buy | hold |
| Avg. price target upside | +280.60% | +325.10% |
| Average volume | 697.98K | 2.19M |
| Shares outstanding | 36.29M | 45.15M |
| Employees | 48 | 59 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Evommune
EVMN stock →Evommune, Inc. operates as a clinical-stage biotechnology company in the United States.
Health Care · Biotechnology: Pharmaceutical Preparations · 48 employees
About Sionna Therapeutics
SION stock →Sionna Therapeutics, Inc., a clinical-stage biopharmaceutical company, researches and develops medicines for the treatment of cystic fibrosis (CF). It develops galicaftor (SION-2222), a transmembrane domain 1 (TMD1)-directed cystic fibrosis transmembrane conductance regulator (CFTR) that has completed Phase 2 trial; navocaftor (SION-3067), a potentiator that has completed Phase 2 trial; SION-109, an intracellular loop 4 directed CFTR corrector that has completed Phase 1 trial; SION-2851, a TMD1-directed CFTR corrector that has completed Phase 1 trial; SION-451, which is nucleotide-binding domain 1 stabilizer in Phase 1 trial; and SION-719, which is nucleotide-binding domain 1 stabilizer in Phase 2a proof-of-concept trial.
Health Care · Biotechnology: Pharmaceutical Preparations · 59 employees
EVMN vs SION FAQ
Which is bigger, Evommune or Sionna Therapeutics?
Evommune (EVMN) is larger, with a market capitalization of $230.09M compared with $223.04M for Sionna Therapeutics (SION).
Are Evommune and Sionna Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.